Photo from wikipedia
Key Points • Third-line CAR T-cell therapy is unlikely to be cost-effective relative to SOC therapies in unselected patients with R/R FL.• The benefits of CAR T-cell therapy in adults… Click to show full abstract
Key Points • Third-line CAR T-cell therapy is unlikely to be cost-effective relative to SOC therapies in unselected patients with R/R FL.• The benefits of CAR T-cell therapy in adults with FL could be clarified with randomized clinical trials and longer term clinical follow-up.
Keywords:
cell;
therapy adults;
cost effectiveness;
cell therapy
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!